The MHRA has approved olezarsen (Tryngolza) for adults with familial chylomicronemia syndrome, showing significant triglyceride reductions and fewer pancreatitis episodes in clinical study
Written By: A. Musharaf Mohammad, BPharm
Reviewed By: Pharmacally Editorial Team
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved olezarsen (Tryngolza) for the treatment of adults with familial chylomicronemia syndrome (FCS), a rare inherited disorder marked by extremely high triglyceride levels that can trigger recurrent pancreatitis and life-threatening complications. The approval was granted on April 10, 2026, to Swedish Orphan Biovitrum AB via the International Recognition Procedure (IRP) Route B.
FCS leads to abnormal accumulation of triglycerides in the bloodstream, increasing the risk of pancreatic inflammation. Patients often experience severe abdominal pain, long-term pancreatic damage, and potentially fatal outcomes. The newly approved therapy provides a targeted option aimed at reducing triglyceride levels and lowering disease burden.
Olezarsen is administered as a subcutaneous injection, typically given in the abdomen, front of the thighs, or the back of the upper arms. Treatment is used alongside strict dietary control, which remains a core component of FCS management.
The approval was supported by a main study involving 66 adults with FCS who followed a controlled diet and received either olezarsen or placebo. After six months, patients treated with Tryngolza experienced an average triglyceride reduction of 32%, while those receiving placebo showed an average increase of 12%. These effects were sustained and further improved after one year, with fewer episodes of acute pancreatitis reported among patients receiving olezarsen.
Julian Beach, Interim Executive Director of Healthcare Quality and Access at the MHRA, said the approval introduces a new treatment option for adults living with FCS, a condition that can cause severe pancreatic inflammation and potentially life-threatening complications. He added that the agency will continue to monitor the medicine’s safety and effectiveness as real-world use expands.
Additional details are available in the Summary of Product Characteristics and Patient Information Leaflet issued following the authorization.
Reference
MHRA approves olezarsen (Tryngolza) for the treatment of familial chylomicronemia syndrome, 10 April 2026, https://www.gov.uk/government/news/mhra-approves-olezarsen-tryngolza-for-the-treatment-of-familial-chylomicronemia-syndrome
About the Writer
Mohamed Musharaf A is a Pharmacy graduate from Ariyur, Puducherry, with a strong interest in data analysis and its application in healthcare. He is particularly interested in using data-driven insights to support pharmacovigilance and medical writing, with a focus on understanding complex datasets and translating them into meaningful, actionable solutions. Known for his dedication to learning and attention to detail, he continuously works to strengthen his analytical and domain knowledge.